ArticleLab on a chip2018
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.
Article in Lab on a chip, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Integration of microphysiological systems with computational and digital twin modeling for pharmaceutical development: a systematic review.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Pooled it
- From monolayer to organoids and multi-organ microphysiological systems: advancing regenerative medicine and precision therapies.Stem cell research & therapy · 2026Review
- PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.Nature communications · 2026Article
- Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.Cancer cell · 2026Article
- Applying microfluidic technology to interpret the tumor immune microenvironment and cancer immunotherapy.Cancer biology & medicine · 2026Review
- Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types.Experimental hematology & oncology · 2026Review
- Bridging cancer cell-intrinsic driver genes and -extrinsic cell-cell communication with Driver2Comm.PLoS computational biology · 2026Article
- A Patient-Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cycling molecular assemblies for Golgi imaging and disruption.Nature communications · 2026Article
- High-throughput spheroid-based assay for functional breast cancer precision medicine facilitated by deep learning.Communications medicine · 2026Article
- Tumor-on-chip's alliance with molecular pathology against metastatic disease.Journal of biomedical science · 2026Review
- Harnessing Next-Generation 3D Cancer Models to Elucidate Tumor-Microbiome Crosstalk.Advanced healthcare materials · 2026Review
- Engineering immune-competent niches: strategies, applications, and translational hurdles in ovarian cancer organoid models.Frontiers in immunology · 2026Review
- Article
- Microgravity-cultured glioblastoma organoids integrated with microfluidic chip for CAR-γδ T evaluation.Communications biology · 2025Article
- Advanced Microfluidics for Single Cell-Based Cancer Research.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies.Cancer immunology research · 2025Article
- Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants.Cell reports. Medicine · 2025Article
- Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform.Cell reports. Medicine · 2025Article
- Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells.Journal of personalized medicine · 2025Review
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for clinical use to test novel cancer therapeutics. To be effective, these platforms need to replicate the continuous interactions that exist between tumor cells and non-tumor cell elements of the tumor microenvironment through direct cell-cell or cell-matrix contact or by the secretion of signaling factors such as cytokines, chemokines and growth factors. Given the challenges of personalized or precision cancer therapy, especially with the advent of novel immunotherapies, a critical need exists for more sophisticated ex vivo diagnostic systems that recapitulate patient-specific tumor biology with the potential to predict response to immune-based therapies in real-time. Here, we present details of a method to screen for the response of patient tumors to immune checkpoint blockade therapy, first reported in Jenkins et al. Cancer Discovery, 2018, 8, 196-215, with updated evaluation of murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS), including evaluation of the requirement for 3D microfluidic culture in MDOTS, demonstration of immune-checkpoint sensitivity of PDOTS, and expanded evaluation of tumor-immune interactions using RNA-sequencing to infer changes in the tumor-immune microenvironment. We also examine some potential improvements to current systems and discuss the challenges in translating such diagnostic assays to the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.